# Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

> **NCT03630991** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 58 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- High Risk Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Myelodysplastic Syndrome
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome
- Very High Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** Edetate Calcium Disodium
- **DIETARY_SUPPLEMENT:** Multivitamin
- **DRUG:** Succimer

## Key facts

- **NCT ID:** NCT03630991
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-11
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03630991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03630991, "Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03630991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*